114 related articles for article (PubMed ID: 15725690)
1. Relationship between insulin resistance and effect of atorvastatin in non-diabetic subjects.
Yoshitomi Y; Ishii T; Kaneki M; Tsujibayashi T; Sakurai S; Nagakura C; Miyauchi A
J Atheroscler Thromb; 2005; 12(1):9-13. PubMed ID: 15725690
[TBL] [Abstract][Full Text] [Related]
2. [A relationship between insulin resistance and reduction in oxidative stress in vivo by atorvastatin].
Hitsumoto T; Iizuka T; Takahashi M; Nakamura K; Shimizu K; Satoh S; Sugiyama Y; Sakurai T; Noike H; Ohsawa H; Watanabe H; Shirai K
J Cardiol; 2004 Dec; 44(6):233-42. PubMed ID: 15638221
[TBL] [Abstract][Full Text] [Related]
3. Effect of atorvastatin on type 2 diabetic dyslipidemia.
Save V; Patil N; Moulik N; Rajadhyaksha G
J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):262-70. PubMed ID: 17220473
[TBL] [Abstract][Full Text] [Related]
4. Effects of atorvastatin on red-blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension.
Kosmidou MS; Hatzitolios AI; Adamidou A; Giannopoulos S; Raikos N; Parharidis G; Milionis HJ
Am J Hypertens; 2008 Mar; 21(3):303-9. PubMed ID: 18202666
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study.
Yoshitomi Y; Ishii T; Kaneki M; Tsujibayashi T; Sakurai S; Nagakura C; Miyauchi A
J Atheroscler Thromb; 2006 Apr; 13(2):108-13. PubMed ID: 16733299
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
[TBL] [Abstract][Full Text] [Related]
9. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
Diabetes Atorvastin Lipid Intervention (DALI) Study Group
Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study.
Anagnostis P; Selalmatzidou D; Polyzos SA; Panagiotou A; Slavakis A; Panagiotidou A; Athyros VG; Karagiannis A; Mikhailidis DP; Kita M
Int J Clin Pract; 2011 Jun; 65(6):679-83. PubMed ID: 21564441
[TBL] [Abstract][Full Text] [Related]
12. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study.
Schrott HG; Knapp H; Davila M; Shurzinske L; Black D
Am Heart J; 2000 Aug; 140(2):249-52. PubMed ID: 10925339
[TBL] [Abstract][Full Text] [Related]
13. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.
Paolisso G; Barbagallo M; Petrella G; Ragno E; Barbieri M; Giordano M; Varricchio M
Atherosclerosis; 2000 May; 150(1):121-7. PubMed ID: 10781642
[TBL] [Abstract][Full Text] [Related]
14. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
[TBL] [Abstract][Full Text] [Related]
15. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
16. Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Acta Cardiol; 2006 Jun; 61(3):263-9. PubMed ID: 16869445
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
Jafari M; Ebrahimi R; Ahmadi-Kashani M; Balian H; Bashir M
J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):123-6. PubMed ID: 12808485
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
19. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
20. Effect of two intensive statin regimens on progression of coronary disease.
Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
